Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
27.05
-0.14 (-0.51%)
At close: Aug 14, 2026, 4:00 PM EDT
26.85
-0.20 (-0.74%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $33.5. The average 1-year stock price forecast is 23.84% higher than the current stock price, while the lowest is $25 (-7.58%) and the highest is $45 (+66.36%).
Price Target: $33.5 (+23.84%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 10 | 10 | 10 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $33 → $36 | Buy | Reiterates | $33 → $36 | +33.09% | Aug 10, 2026 |
| Needham | Needham | Buy Maintains $34 | Buy | Maintains | $34 | +25.69% | Aug 4, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $36 → $38 | Buy | Reiterates | $36 → $38 | +40.48% | Jul 28, 2026 |
| UBS | UBS | Buy Reiterates $23 → $31 | Buy | Reiterates | $23 → $31 | +14.60% | Jul 22, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $25 | Hold | Maintains | $25 | -7.58% | Jul 14, 2026 |
Financial Forecast
Revenue This Year
755.34M
from 83.98M
Increased by 799.42%
Revenue Next Year
120.76M
from 755.34M
Decreased by -84.01%
EPS This Year
1.79
from -3.05
EPS Next Year
-1.44
from 1.79
EPS and Forward PE are based on non-GAAP adjusted numbers.